|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||35.60 - 36.30|
|52 Week Range||20.24 - 56.80|
|Beta (5Y Monthly)||1.66|
|PE Ratio (TTM)||151.02|
|Earnings Date||May 02, 2022 - May 06, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||71.08|
Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.
Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2022, and provided business highlights. “The Phase 1 study of DNL919 (ATV:TREM2) is now underway, making this our third BBB Transport Vehicle (TV)-enabled program,